Universal Beteiligungs und Servicegesellschaft mbH Invests $14.43 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 136,631 shares of the medical equipment provider's stock, valued at approximately $14,432,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of Zimmer Biomet as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in ZBH. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet in the fourth quarter valued at about $473,000. KLCM Advisors Inc. acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $7,825,000. Van ECK Associates Corp raised its holdings in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after acquiring an additional 218,688 shares during the last quarter. MFG Wealth Management Inc. acquired a new position in Zimmer Biomet in the 4th quarter valued at $1,506,000. Finally, Gries Financial LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $866,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several analyst reports. JPMorgan Chase & Co. cut their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Robert W. Baird lowered their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Canaccord Genuity Group lowered their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Finally, Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $111.53.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.70% of the company's stock.

Zimmer Biomet Stock Down 1.3%

Zimmer Biomet stock traded down $1.22 during trading on Friday, reaching $92.12. 3,505,131 shares of the company's stock were exchanged, compared to its average volume of 1,800,204. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company's 50-day moving average is $99.99 and its two-hundred day moving average is $104.76. The firm has a market cap of $18.23 billion, a price-to-earnings ratio of 20.70, a PEG ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm's revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.94 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.04%. Zimmer Biomet's payout ratio is currently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.